Table 3.
Strong expression of MAPK pathway proteins in HCC patients in both tumor and adjacent cirrhosis according to CLD etiology.
| Etiology | KRAS | BRAF | MEK | ERK-1/2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor n (%) | Cirrhosis n (%) | p value | Tumor n (%) | Cirrhosis n (%) | p value | Tumor n (%) | Cirrhosis n (%) | p value | Tumor n (%) | Cirrhosis n (%) | p value | |
| Viral | 11/41 (26.8) | 0/33 (0.0) | 0.004b | 7/40 (17.5) | 3/32 (9.4) | 0.755b | 2/41 (4.9) | 1/32 (3.1) | 1.000b | 7/32 (21.9) | 2/32 (6.3) | 0.150b |
|
| ||||||||||||
| Nonviral | 3/39 (7.7) | 2/34 (5.9) | 1.000b | 11/39 (28.2) | 8/30 (26.6) | 1.000b | 2/39 (5.1) | 0/32 (0.0%) | 0.563b | 6/32 (18.8) | 0/30 (0.0) | 0.390b |
|
| ||||||||||||
| p value | 0.024a | 0.049b | — | 0.257a | 0.075a | — | 1.000b | 1.000b | — | 0.756a | 0.492b | — |
Data are expressed as the absolute number/total of samples analyzed (percentage). MAPK, mitogen-activated protein kinases; HCC, hepatocellular carcinoma; CLD, chronic liver disease. aChi-square test. bFisher's exact test.